Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Ubrelvy and Qulipta Pregnancy Exposure Registry EMPRESS: An Observational, Prospective Study to Assess the Safety of Ubrelvy (Ubrogepant) and Qulipta (Atogepant) During Pregnancy

NCT05158894 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT05158894
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05158894 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Ubrelvy and Qulipta Pregnancy Exposure Registry EMPRESS: An Observational, Prospective Study to Assess the Safety of Ubrelvy (Ubrogepant) and Qulipta (Atogepant) During Pregnancy
Lead sponsor
AbbVie
Phase
Observational
Overall status
Recruiting
Start date
January 10, 2023
Completion date
January 31, 2036
Enrollment
1,884 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

migraine